GlobeNewsWire
24 Jun 2026, 12:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
NeOnc expects to report topline results from its fully enrolled NEO100-01 Phase 2a trial by the end of July. — Phase 2a topline data is a primary clinical catalyst that typically causes significant price volatility in biotech stocks.
+0.80CEO Amir Heshmatpour has invested over $500,000 in open-market purchases recently, with total insider buying near $1 million over the last year. — Significant insider buying is generally viewed as a strong bullish signal of management's confidence in upcoming milestones.
+0.50The UAE Department of Health – Abu Dhabi granted IND status to NEO100 for adult and pediatric clinical protocols. — Expanding regulatory footprints into international markets reduces geographic risk and opens new patient recruitment pathways.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
NeOnc has access to a $75 million at-the-market facility and a $10 million line of credit. — Confirmed liquidity reduces immediate bankruptcy risk and ensures the company can fund near-term operations.
+0.20Which stocks this story touches
The company secured multiple IND authorizations in the UAE, has strong insider buying, and has upcoming Phase 2a clinical data results.
Mentioned only as an institutional holder of NTHI shares.
Mentioned only as an institutional holder of NTHI shares.
Mentioned only as an institutional holder of NTHI shares.
[a_to_b] Bank of America is listed as an institutional holder of NeOnc Technologies Holdings.
[a_to_b] State Street is listed as an institutional holder of NeOnc Technologies Holdings.
[a_to_b] Barclays is listed as an institutional holder of NeOnc Technologies Holdings.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
14h ago
